Drugs / Gallium maltolate
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07515924 | Jun 2026 → Sep 2027 expected | glioblastoma | Medical College of Wisconsin | Not yet recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT07331064 | May 2026 → Nov 2030 expected | atypical teratoid rhabdoid tumor, diffuse intrinsic pontine glioma | Sarah Rumler | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT04319276 | Nov 2022 → Feb 2025 overdue | glioblastoma | Medical College of Wisconsin | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00050687 | Jun 2001 → Mar 2005 | plasma cell myeloma, prostate neoplasm, urinary bladder neoplasm | Titan Pharmaceuticals | Terminated | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06404034 | — | glioblastoma | Imaging Biometrics, LLC | Available | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gallium maltolate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04319276 ↗ |
| Known as | GaM | “Gallium Maltolate (GaM) and what doses of GaM are safe for people to take.” NCT07331064 ↗ |
| Modality | Small molecule | “oral small-molecule iron mimetic” NCT07331064 ↗ |
| Route | Oral | “Patients will receive oral gallium maltolate twice daily for 28-consecutive days followed by 14 days off treatment.” NCT00050687 ↗ |